Performance-Based Risk-Sharing Arrangements: An Updated International Review

被引:0
|
作者
Josh J. Carlson
Shuxian Chen
Louis P. Garrison
机构
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program
来源
PharmacoEconomics | 2017年 / 35卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Enthusiasm for performance-based risk-sharing arrangements (PBRSAs) continues but at variable pace across countries. Our objective was to identify and characterize publicly available cases and related trends for these arrangements. We performed a review of PBRSAs from 1993 to 2016 using the University of Washington PBRSA Database. Arrangements were categorized according to a previously published taxonomy. Macro-level trends were identified related to the timing of adoption, countries involved, types of arrangements, and disease areas. Our search yielded 437 arrangements. Among these, 183 (41.9%) were categorized as currently active, while 58.1% have expired. Five main types of arrangements have been identified, namely coverage with evidence development (149 cases, 34.1%), performance-linked reimbursement (104 cases, 23.8%), conditional treatment continuation (78 cases, 17.8%), financial or utilization (71 cases, 16.2%), and hybrid schemes with multiple components (35 cases, 8.0%). The pace of adoption varies across countries but has renewed an upward trend after a lull in 2012/2013. Conditions in the USA may be changing toward a more favorable environment of PBRSAs. Interest in PBRSAs remains high, suggesting they are a viable coverage and reimbursement mechanism for a wide range of medical products.
引用
收藏
页码:1063 / 1072
页数:9
相关论文
共 50 条
  • [41] Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain)
    Guarga, Laura
    Gasol, Montse
    Reyes, Anna
    Roig, Marta
    Alonso, Enric
    Clopes, Ana
    Delgadillo, Joaquim
    [J]. VALUE IN HEALTH, 2022, 25 (05) : 803 - 809
  • [42] Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement
    Taryn A. G. Quinlan
    Brock Schroeder
    Sue Kwon
    Jane F. Barlow
    Michael S. Sherman
    Heather D. Anderson
    Garth Wright
    R. Brett McQueen
    [J]. PharmacoEconomics - Open, 2021, 5 : 449 - 458
  • [43] ONE DAY MONEY WILL ONLY BE SPENT ON EFFECTIVE DRUGS ... FROM PAYERS' ASPIRATIONS TO PERFORMANCE-BASED RISK-SHARING OPERATIONS
    Ethgen, O.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A164 - A164
  • [44] Optimal investment strategies and risk-sharing arrangements for a hybrid pension plan
    Wang, Suxin
    Lu, Yi
    [J]. INSURANCE MATHEMATICS & ECONOMICS, 2019, 89 : 46 - 62
  • [45] INTERNATIONAL RISK-SHARING AND CURRENCY UNIONS: THE CFA ZONES
    Yehoue, Etienne B.
    [J]. JOURNAL OF INTERNATIONAL DEVELOPMENT, 2011, 23 (07) : 936 - 958
  • [46] DESIGNING A PERFORMANCE-BASED RISK SHARING ARRANGEMENT FOR ADUCANUMAB
    Zhou, N.
    Lee, Y. S.
    Xia, Z.
    Pan, Z.
    Levy, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S269 - S269
  • [47] International risk-sharing in the short run and in the long run
    Baxter, Marianne
    [J]. CANADIAN JOURNAL OF ECONOMICS-REVUE CANADIENNE D ECONOMIQUE, 2012, 45 (02): : 376 - 393
  • [48] Growth and risk-sharing with incomplete international assets markets
    Devereux, MB
    Saito, M
    [J]. JOURNAL OF INTERNATIONAL ECONOMICS, 1997, 42 (3-4) : 453 - 481
  • [49] RISK-SHARING IN INTERNATIONAL-TRADE - AN ANALYSIS OF COUNTERTRADE
    AMANN, E
    MARIN, D
    [J]. JOURNAL OF INDUSTRIAL ECONOMICS, 1994, 42 (01): : 63 - 77
  • [50] Insurance-based risk-sharing agreements
    Augustin Terlinden
    Amine Aissaoui
    Olivier Ethgen
    [J]. Journal of Pharmaceutical Policy and Practice, 8 (Suppl 1)